Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSOrforglipron activates the same GLP-1 receptor as Ozempic without a peptide backbone. Tirzepatide still has the efficacy lead. Here is what the peptide pipeline loses and what it keeps.
Tirzepatide produced 22% weight loss vs 15% for semaglutide in a head-to-head trial. The bigger number wins the weight race but comes with a bigger muscle cost. A third hormone may fix it.
New real-world data suggests tirzepatide loses more muscle than semaglutide at matched weight reduction. The next generation of drugs is adding a glucagon receptor to protect muscle.
Svetlana Mojsov identified the active form of GLP-1 in 1983. Every Ozempic, Wegovy, Mounjaro, and Zepbound traces back to her work. Public credit took forty years to catch up.
Orforglipron is the first pill in the Ozempic class. In a two-year diabetes trial of 2,749 adults, it cut deaths by more than half compared to standard insulin therapy.